Work

High-dose treatment with ADXS11-001, a listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy, in women with cervical cancer

Year: 2015

Type: article

Abstract: Meeting abstracts Survival of patients with persistent and recurrent cervical cancer is dismal, and improvement remains a large unmet need. ADXS11-001 is a live, attenuated, bioengineered Lm -LLO immunotherapy for the treatment of human papillomavirus (HPV)-associated cancers such as cervical

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-3-s2-p151

Authors: Sharad Ghamande, David Mauro, Cheryl Price, Donna Wheatley, John Janik, Samir N Khleif

Institutions: Augusta University, Advaxis (United States)

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490